Isaia G, Di Stefano M, Roggia C, Ardissone P, Rosina F
Department of Internal Medicine, University of Turin, Turin, Italy.
Forum (Genova). 1998 Jan-Mar;8(1):28-38.
Osteopenia is a recognised complication of cholestatic liver diseases (CLD), usually ascribed to metabolic bone diseases such as osteomalacia or osteoporosis, with a prevalence from 10 to 56%, depending on the nature of liver disease. Primary biliary cirrhosis (PBC) is the condition causing osteopenia more frequently, but other cholestatic liver diseases like primary sclerosing cholangitis (PSC), haemochromatosis and alcoholic liver disease are also frequently associated with this disorder. The pathogenesis of bone disease in both adults and children with chronic cholestasis is not completely understood. There has been considerable disagreement regarding the relative importance of osteomalacia versus osteoporosis as the factors leading to osteopenia of liver disease. Osteopenia predisposes to atraumatic fractures, particularly in PBC patients undergoing orthotopic liver transplantation and treated with high corticosteroid doses. Bone mineral density measurement is the best way to assess the presence and severity of osteopenia in CLD patients, while laboratory tests give important information about the metabolic status of the bone. In this review prevalence data, diagnostic tools, pathophysiology and treatment of osteopenia in CLD are discussed.
骨质减少是胆汁淤积性肝病(CLD)的一种公认并发症,通常归因于诸如骨软化症或骨质疏松症等代谢性骨病,其患病率在10%至56%之间,具体取决于肝病的性质。原发性胆汁性肝硬化(PBC)是导致骨质减少最常见的病症,但其他胆汁淤积性肝病,如原发性硬化性胆管炎(PSC)、血色素沉着症和酒精性肝病也常与此病症相关。慢性胆汁淤积的成人和儿童骨病的发病机制尚未完全明确。关于骨软化症与骨质疏松症作为导致肝病骨质减少的因素的相对重要性,一直存在相当大的分歧。骨质减少易引发非创伤性骨折,尤其是在接受原位肝移植并接受高剂量皮质类固醇治疗的PBC患者中。骨密度测量是评估CLD患者骨质减少的存在和严重程度的最佳方法,而实验室检查可提供有关骨骼代谢状态的重要信息。在本综述中,将讨论CLD中骨质减少的患病率数据、诊断工具、病理生理学和治疗方法。